Research discussion is not a recommendation. Do not buy or use unauthorized products, including products labelled “research use only” or “not for human consumption.”

What it is

Retatrutide is an investigational peptide-based drug candidate designed to activate GIP, GLP-1, and glucagon receptors. It is being studied in human clinical trials for metabolic indications.

Investigation is not authorization

Published trials can provide meaningful human evidence while a product remains investigational. Trial results do not permit unrelated businesses to manufacture or sell their own version, and a registered trial does not establish that a product is available to patients.

Canadian context

Health Canada’s April 2026 advisory names retatrutide among unauthorized injectable peptide drugs found in the online market. No authorized retatrutide drug product was identified in the Drug Product Database on the date checked.

Key unknowns

Ongoing trials continue to define benefits, adverse effects, longer-term outcomes, and appropriate use. Online products labelled retatrutide are not the same as sponsor-manufactured investigational products used under a clinical-trial protocol.

Source trail

Primary sources

  1. Health Canada - 2026 injectable peptide advisory
  2. Health Canada - Drug Product Database
  3. ClinicalTrials.gov - Retatrutide studies
Status can change. Check Health Canada’s Drug Product Database and the exact finished product before relying on this profile. This page is general education, not medical advice or a product recommendation. Full disclaimer.